Two intracellular traffics of a growth factor
Project/Area Number |
16590223
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
General medical chemistry
|
Research Institution | Nagoya University |
Principal Investigator |
KADOMATSU Kenji Nagoya University, Graduate School of Medicine, Professor, 大学院・医学系研究科, 教授 (80204519)
|
Co-Investigator(Kenkyū-buntansha) |
MURAMATSU Hisako Nagoya University, Graduate School of Medicine, Associate Professor, 大学院・医学系研究科, 助教授 (50182134)
|
Project Period (FY) |
2004 – 2005
|
Project Status |
Completed (Fiscal Year 2005)
|
Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2005: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2004: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
Keywords | endocytosis / growth factor / nuclear transfer / midkine / intracellular traffic / nephritis / cisplatin / diabetes mellitus / プロテアゾーム |
Research Abstract |
This study addressed two traffics of the growth factor midkine (MK), namely degradation and nuclear targeting. MK is implicated in cancer development, neuronal survival and differentiation, and inflammation. LDL receptor-related protein (LRP) is one of the receptors for MK. We previously found that MK is endocytosed via LRP, and is further translocated to the nucleus, this being important for the anti-apoptotic activity of MK. In the present study, we found that MK goes into the lysosomal as well as proteasomal degradation pathways after endocytosis. Inhibitors for the lysosome and proteasome suppressed MK degradation after endocytosis. The intranuclear degradation of MK was only inhibited by a proteasomal inhibitor, i.e., not lysosomal inhibitors. The N-terminal half of MK is degraded via the proteasome faster than the C-terminal half. The C-terminal half was responsible for the nuclear targeting of MK. Our findings support the idea that endocytosed MK enters both the two degradation pathways, and at least a part of endocytosed MK is translocated to the cytoplasm from the endosome, and is further transferred to the nucleus. We report additional findings that MK is involved in the pathogenesis of interstitial nephritis, cisplatin-induced nephritis and diabetic nephropathy.
|
Report
(3 results)
Research Products
(24 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion.2005
Author(s)
Sato, W., Takei, Y., Yuzawa, Y., Matsuo, S., Kadomatsu, K., Muramatsu T.
-
Journal Title
Related Report
-
-
[Journal Article] Proteasomal degradation of the nuclear targeting growth factor midkine.2004
Author(s)
Suzuki, N., Shibata, Y., Urano, T., Murohara, T., Muramatsu, T., Kadomatsu, K.
-
Journal Title
J. Biol. Chem. 279
Pages: 17785-17791
Related Report
-
-
-
[Journal Article] Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage.2004
Author(s)
Kawai, H., Sato, W., Yazawa, Y., Kosugi, T., Matsuo, S., Takei, Y., Kadomatsu, K.
-
Journal Title
Am.J.Pathol. 165
Pages: 1603-1612
Related Report